Print
|
Close
Clinical Trial Search Results
**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts...
Click here to learn more about clinical trials
.
All Clinical Trials
All Clinical Trials
NCI ID
Cancer Type
Trial Name
NCI ID
Cancer Type
Trial Name
Records 1 - 715 of 715
1.
1. Use of Definity® Contrast Agent for Ultrasound of Intraocular Tumors
Cancer Type
Eye Cancer
NCI ID
NCT01930968
Protocol IDs
Treatment Sites (1)
Emory University Hospital - Atlanta
Atlanta
2.
18F-Fluoride PET/CT Versus 99mTc-MDP Scanning for Detecting Bone Metastases: A Randomized, Multi-Center Trial to Compare Two Bone Imaging Techniques
Cancer Type
Prostate Cancer
NCI ID
NCT00882609
Protocol IDs
Treatment Sites (1)
Southcoast Health
Savannah
3.
A 2 Cohort, Non-comparative, Pivotal Study Evaluating the Efficacy of Tipifarnib in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC) With HRAS Mutations (AIM-HN) and the Impact of HRAS Mutations on Response to First Line Systemic Therapies for HNSCC (SEQ-HN)
Cancer Type
Head and Neck Cancer
NCI ID
NCT03719690
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
4.
A Clinical Study to Demonstrate Safety and Efficacy of E7777 in Persistent or Recurrent Cutaneous T-Cell Lymphoma
Cancer Type
Lymphoma, Skin Cancer (Non-Melanoma)
NCI ID
NCT01871727
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
5.
A Comprehensive Approach to Improve Medication Adherence in Pediatric ALL
Cancer Type
Leukemia
NCI ID
NCT01503632
Protocol IDs
Treatment Sites (1)
Aflac Cancer and Blood Disorders Center of Children’s at Egleston
Atlanta
Howard M. Katzenstein, MD
404-785-0853
6.
A Confirmatory, Prospective, Open-label, Multi-centre Phase 3 Study to Evaluate Diagnostic Performance of Zirconium-labelled Girentuximab to Non-invasively Detect ccRCC by PET / CT Imaging in Patients With Indeterminate Renal Masses
Cancer Type
NCI ID
NCT03849118
Protocol IDs
89Zr-TLX250-003
NCI-2020-02184
7.
A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients With Stage 0-III Colon Cancer, Phase III - Preventing Adenomas of the Colon With Eflornithine and Sulindac (PACES)
Cancer Type
Unknown Primary
NCI ID
NCT01349881
Protocol IDs
Treatment Sites (8)
Dwight David Eisenhower Army Medical Center
Augusta
Erik Rupard
706-787-2100
Emory Saint Joseph's Hospital
Atlanta
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
Nancy N. and J.C. Lewis Cancer Research Pavilion at St. Joseph Candler
Savannah
Alaina Underberg
912-819-5778
Northeast Georgia Medical Center - Gainesville
Gainesville
Trena Davis
770-219-8822
Phoebe Cancer Center at Phoebe Putney Memorial Hospital
Albany
Dept of Clinical Research
(229) 312-0406
Piedmont Columbus Regional
Columbus
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
8.
A First -in Human Phase I, Non-randomized, Open-label, Multi-center Dose Escalation Trial of BI 764532 Administered by Repeated Intravenous Infusions in Patients With Small Cell Lung Carcinoma and Other Neuroendocrine Neoplasms Expressing DLL3
Cancer Type
NCI ID
NCT04429087
Protocol IDs
1438-0001
NCI-2021-01392
2019-000729-31
9.
A First-in-Human, Multicenter, Open-Label, Phase 1 Dose-Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TAB004 in Subjects With Advanced Solid Malignancies Including Lymphoma
Cancer Type
NCI ID
NCT04137900
Protocol IDs
TAB004-01
NCI-2020-00511
10.
A Four Arm Randomized Phase II Study Comparing Single-Agent Olaparib, Single Agent Cediranib, the Combination of Cediranib / Olaparib and the Combination of Olaparib / Wee1 Inhibitor AZD1775 in Women with Recurrent, Persistent or Metastatic Endometrial Cancer (EEC)
Cancer Type
Endometrial Cancer
NCI ID
NCT03660826
Protocol IDs
Treatment Sites (4)
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
Grady Memorial Hospital
Atlanta
Piedmont Hospital - Atlanta
Atlanta
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
11.
A Genome-Wide Association Study in Participants Experiencing Breast Cancer Events in High-Risk Postmenopausal Women Receiving Selective Estrogen Receptor Modulators on NSABP Trials P-1 and P-2
Cancer Type
Breast Cancer
NCI ID
NCT00967239
Protocol IDs
MC083I
NCI-2009-01112
CDR0000638644
NSABP-MC083I
12.
A Global Randomized Multicenter Phase 3 Trial of JCAR017 Compared to Standard of Care in Adult Subjects With High-risk, Second-line, Transplant-eligible Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphomas (TRANSFORM).
Cancer Type
Lymphoma
NCI ID
NCT03575351
Protocol IDs
Treatment Sites (1)
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
13.
A Master Protocol for Biomarker-Based Treatment of AML (The Beat AML Trial)
Cancer Type
Myelodysplastic Syndromes (MDS)
NCI ID
NCT03013998
Protocol IDs
Treatment Sites (1)
Emory University Hospital - Atlanta
Atlanta
14.
A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study)
Cancer Type
Lung Cancer
NCI ID
NCT03851445
Protocol IDs
Treatment Sites (14)
Atlanta Cancer Care - Alpharetta
Alpharetta
Kristin Sieverding
770-777-1315
Atlanta Cancer Care - Conyers
Conyers
404-303-3355
Atlanta Cancer Care - Cumming
Cumming
Renee Gaiter
770-205-5292 x1041
Atlanta Cancer Care - Decatur
Decatur
404-303-3355
Atlanta Cancer Care - Stockbridge
Jonesboro
Andrena Jefferson
678 466-2069
Atlanta Cancer Care - Tower
Atlanta
404-303-3355
Georgia Cancer Specialists - Athens
Athens
Cynthia Pirkle
Georgia Cancer Specialists - Canton
Canton
Georgia Cancer Specialists - CenterPointe
Sandy Springs
Anila Lokhandwala
404-256-4777 ext 9242
Georgia Cancer Specialists - Kennestone
Marietta
Greta Dudley
Georgia Cancer Specialists - Macon-Coliseum
Macon
Sonia Hernandez
478-745-6130 x8152
Georgia Cancer Specialists - Stemmer
Decatur
Nina Patel
770-496-5555
Nancy N. and J.C. Lewis Cancer Research Pavilion at St. Joseph Candler
Savannah
Alaina Underberg
912-819-5778
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
15.
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients With Hematologic Malignancies and Other Indications
Cancer Type
Multiple Primaries
NCI ID
NCT01351545
Protocol IDs
Treatment Sites (4)
Aflac Cancer and Blood Disorders Center of Children’s at Egleston
Atlanta
Howard M. Katzenstein, MD
404-785-0853
Aflac Cancer and Blood Disorders Center of Children’s at Scottish Rite
Atlanta
Karen Querubin, BSN
404-785-2215
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
16.
A Multicenter Phase Ib Trial for Patients With Advanced Hematologic Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation With TregGraft, a T-cell-Depleted Graft With Additional Infusion of Conventional T Cells and Regulatory T Cells
Cancer Type
NCI ID
NCT04013685
Protocol IDs
TRGFT-201
NCI-2019-08529
17.
A Multicenter Phase II Study of Vaccines to Prevent Recurrence in Patients with HER-2 Positive Breast Cancer
Cancer Type
Breast Cancer
NCI ID
NCT03384914
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
18.
A Multi-Center Randomised Open-Label Phase 2 Study to Assess the Safety, Tolerability and Efficacy of Fimaporfin-Induced Photochemical Internalisation of Gemcitabine Complemented by Gemcitabine / Cisplatin Chemotherapy Versus Gemcitabine / Cisplatin Alone in Patients With Inoperable Cholangiocarcinoma
Cancer Type
NCI ID
NCT04099888
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
19.
A Multicenter Safety Study of Unlicensed, Investigational Cryopreserved Cord Blood Units Manufactured by the National Cord Blood Program and Provided for Unrelated Hematopoietic Stem Cell Transplantation of Pediatric and Adult Patients
Cancer Type
Hodgkin Lymphoma, Lymphoma, Non-Hodgkin Lymphoma, Skin Cancer (Non-Melanoma)
NCI ID
NCT01656603
Protocol IDs
Treatment Sites (1)
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
20.
A Multicenter Study of Hematopoietic Stem Cell Donor Safety and Quality of Life
Cancer Type
Quality of Life
NCI ID
NCT00948636
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
21.
A Multicenter, Open Label Phase I/II Study of CEP-701 (Lestaurtinib) in Adults with Myelofibrosis
Cancer Type
Myelodysplastic Syndromes (MDS)
NCI ID
NCT00668421
Protocol IDs
104
NCI-2012-00298
22.
A Multicenter, Open Label, Phase III Extension Trial to Study the Long-term Safety and Efficacy in Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab Trial
Cancer Type
Unknown Primary
NCI ID
NCT03486873
Protocol IDs
Treatment Sites (1)
Emory University School of Medicine
Atlanta
23.
A Multicenter, Open-Label Study of CMX001 Treatment of Serious Diseases or Conditions Caused By dsDNA Viruses
Cancer Type
Bone and Soft Tissue (including Sarcoma)
NCI ID
NCT01143181
Protocol IDs
CMX001-350
1986
24.
A Multicenter, Open-label Study to Determine the Maximum Tolerated Dose, Assess the Safety and Tolerability, Pharmacokinetics and Preliminary Efficacy of CC-220 Monotherapy and in Combination With Dexamethasone in Subjects With Relapsed and/or Refractory Multiple Myeloma
Cancer Type
Multiple Myeloma
NCI ID
NCT02773030
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
25.
A Multicenter, Open-label, Phase 2 Study of Intratumoral CMP-001 in Combination With Intravenous Nivolumab in Subjects With Refractory Unresectable or Metastatic Melanoma
Cancer Type
NCI ID
NCT04698187
Protocol IDs
CMP-001-010
NCI-2021-00309
26.
A Multi-Center, Open-Label, Phase 2 Study to Evaluate Safety and Efficacy of U3-1402 in Subjects With Advanced or Metastatic Colorectal Cancer (CRC)
Cancer Type
NCI ID
NCT04479436
Protocol IDs
U31402-A-U202
NCI-2020-05885
2019-004418-32
27.
A Multi-Center, Phase 2, Open-label, Parallel Cohort Study of Efficacy and Safety of Duvelisib in Patients With Relapsed or Refractory Peripheral T Cell Lymphoma (PTCL)
Cancer Type
Lymphoma
NCI ID
NCT03372057
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
28.
A Multi-Center, Phase I / II Study of Combination APG-1252 Plus Paclitaxel in Patients With Relapsed / Refractory Small Cell Lung Cancer
Cancer Type
NCI ID
NCT04210037
Protocol IDs
APG1252SU101
NCI-2020-00670
29.
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Trial of Tecemotide Versus Placebo in Subjects With Completed Concurrent Chemo-radiotherapy for Unresectable Stage III Non-small Cell Lung Cancer (NSCLC)
Cancer Type
Lung Cancer
NCI ID
NCT02049151
Protocol IDs
Treatment Sites (1)
Phoebe Cancer Center at Phoebe Putney Memorial Hospital
Albany
Dept of Clinical Research
(229) 312-0406
30.
A Multi-Center, Randomized, Open Label Trial to Evaluate the Utility of Serum Hepcidin Levels to Predict Response to Oral or IV Iron and Compare the Safety, Effect on Quality of Life, and Resource Utilization of Injectafer vs. Intravenous Iron Standard of Care for the Treatment of Iron Deficiency Anemia (IDA) in an Infusion Center Setting
Cancer Type
Breast Cancer
NCI ID
NCT01950247
Protocol IDs
1VIT13032
31.
A Multicenter, Randomized, Open-Label Phase 2b Study to Investigate the Efficacy and Safety of Aldoxorubicin Compared to Topotecan in Subjects With Metastatic Small Cell Lung Cancer Who Either Relapsed or Were Refractory to Prior Chemotherapy
Cancer Type
Lung Cancer
NCI ID
NCT02200757
Protocol IDs
Treatment Sites (9)
Northwest Georgia Oncology Centers - Austell
Austell
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Bremen
Bremen
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Carrollton
Carrollton
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Cartersville
Cartersville
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Douglasville
Douglasville
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Jasper
Jasper
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Marietta
Marietta
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Paulding
Hiram
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Villa Rica
Villa Rica
Mary Gilley
770-281-5131
32.
A Multicenter, Randomized, Open-label, Phase 3 Trial Comparing Selpercatinib to Physicians Choice of Cabozantinib or Vandetanib in Patients With Progressive, Advanced, Kinase Inhibitor Naïve, RET-Mutant Medullary Thyroid Cancer (LIBRETTO-531)
Cancer Type
NCI ID
NCT04211337
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
33.
A Multi-Center, Randomized, Phase III Study of Rituximab Versus Iodine I 131 Tositumomab Therapy for Patients With Relapsed Follicular Non-Hodgkin's Lymphoma
Cancer Type
Non-Hodgkin Lymphoma
NCI ID
NCT00078598
Protocol IDs
Treatment Sites (1)
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
34.
A Multi-Institutional Phase II Study to Evaluate Efficacy and Safety of Talazoparib, Radiotherapy and Atezolizumab in gBRCA 1 / 2 Negative Patients with PD-L1+ Metastatic Triple Negative Breast Cancer (TARA)
Cancer Type
NCI ID
NCT04690855
Protocol IDs
HCRNBRE19-433
NCI-2020-05880
STUDY00001245
WINSHIP5099-20
35.
A Multinational, Randomized, Open-Label Phase III Study of Custirsen (TV-1011/OGX-011) In Combination With Docetaxel Versus Docetaxel As A Second-Line Treatment In Patients With Advanced or Metastatic (Stage IV) Non-Small Cell Lung Cancer
Cancer Type
Lung Cancer
NCI ID
NCT01630733
Protocol IDs
TV1011-LC-303
2012-002447-14
36.
A Multi-site, Prospective, Observational Study in US Patients with Advanced Melanoma
Cancer Type
Melanoma
NCI ID
Protocol IDs
CA184-199
IMPULSE
BMS CA184-199
37.
A Non-Randomized Prospective Clinical Trial Comparing the Non-Inferiority of Salpingectomy to Salpingo-Oophorectomy to Reduce the Risk of Ovarian Cancer among BRCA1 Carriers [SOROCk]
Cancer Type
NCI ID
NCT04251052
Protocol IDs
Treatment Sites (2)
Nancy N. and J.C. Lewis Cancer Research Pavilion at St. Joseph Candler
Savannah
Alaina Underberg
912-819-5778
Summit Cancer Care at the Nancy N. Lewis and J.C. Lewis Cancer & Research Pavilion
Savannah
38.
A Non-randomized, Open-label, Multi-center, Phase I / II Study of Phosphatidylinositol-3-kinase (PI3K) Inhibitor Copanlisib in Pediatric Patients With Relapsed / Refractory Solid Tumors or Lymphoma
Cancer Type
Bone and Soft Tissue (including Sarcoma), Ewing Sarcoma, Lymphoma, Neuroblastoma
NCI ID
NCT03458728
Protocol IDs
Treatment Sites (1)
Aflac Cancer and Blood Disorders Center of Children’s at Egleston
Atlanta
Howard M. Katzenstein, MD
404-785-0853
39.
A Novel Method of Screening for Ovarian Cancer Using Gynecologic Fluids and Mucus
Cancer Type
NCI ID
NCT01787656
Protocol IDs
USA-MCI GON-1.04
NCI-2015-00690
13-005
40.
A Pediatric Brain Tumor Consortium Phase I / II and Surgical Study of CX-4945 in Patients with Recurrent SHH Medulloblastoma
Cancer Type
NCI ID
NCT03904862
Protocol IDs
Treatment Sites (1)
Aflac Cancer and Blood Disorders Center of Children’s at Egleston
Atlanta
Howard M. Katzenstein, MD
404-785-0853
41.
A Phase 1 / 1b, Open-Label, Dose-Escalation and Expansion Study of Entrectinib (RXDX 101) in Children and Adolescents With Recurrent or Refractory Solid Tumors and Primary CNS Tumors, With or Without TRK, ROS1, or ALK Fusions
Cancer Type
Neuroblastoma
NCI ID
NCT02650401
Protocol IDs
Treatment Sites (1)
Emory University Hospital - Atlanta
Atlanta
42.
A Phase 1 / 2 Feasibility, Safety, and Activity Study of PSCA-Specific Chimeric Antigen Receptor Engineered T Cells (BPX-601) in Subjects With Previously Treated Advanced Solid Tumors
Cancer Type
NCI ID
NCT02744287
Protocol IDs
BP-012
NCI-2019-02615
43.
A Phase 1 / 2 Multicenter, Open-label, Study to Determine the Recommended Dose and Regimen, and Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Subjects With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)
Cancer Type
NCI ID
NCT03989414
Protocol IDs
CC-92480-MM-002
NCI-2019-04130
2018-004767-31
U1111-1233-5619
44.
A Phase 1 / 2 Open Label, Multicenter, Dose Escalation and Expansion Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM43239 in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)
Cancer Type
NCI ID
NCT03850574
Protocol IDs
HM-FLTI-101
NCI-2019-06837
45.
A Phase 1 / 2 Study of CPI-0209 Monotherapy and in Combination With Other Therapy in Patients With Advanced Solid Tumors
Cancer Type
NCI ID
NCT04104776
Protocol IDs
0209-01
NCI-2020-01007
46.
A Phase 1 / 2 Study of In Situ Vaccination With Tremelimumab and IV Durvalumab (MEDI4736) Plus the Toll-like Receptor Agonist PolyICLC in Subjects With Advanced, Measurable, Biopsy-accessible Cancers
Cancer Type
Melanoma
NCI ID
NCT02643303
Protocol IDs
LUD2014-011
NCI-2017-01766
47.
A Phase 1 / 2 Study of Oral LOXO-305 in Patients With Previously Treated Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma (CLL / SLL) or Non-Hodgkin's Lymphoma (NHL)
Cancer Type
Leukemia, Lymphoma, Non-Hodgkin Lymphoma
NCI ID
NCT03740529
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
48.
A Phase 1 / 2 Study of Pembrolizumab plus Pralatrexate for Treatment of Relapsed or Refractory Peripheral T-Cell Lymphomas
Cancer Type
NCI ID
NCT03598998
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
49.
A Phase 1 / 2 Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of the Oral EGFR / HER2 Inhibitor TAK-788 (AP32788) in Non-Small Cell Lung Cancer
Cancer Type
Lung Cancer, Unknown Primary
NCI ID
NCT02716116
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
50.
A Phase 1 / 2 Study of the TRK Inhibitor LOXO-195 in Adult and Pediatric Subjects With Previously Treated NTRK Fusion Cancers
Cancer Type
NCI ID
NCT03215511
Protocol IDs
Treatment Sites (2)
Emory Saint Joseph's Hospital
Atlanta
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
51.
A Phase 1 / 2 Study of TPX-0046, A Novel Oral RET / SRC Inhibitor in Adult Subjects With Advanced / Metastatic Solid Tumors Harboring Oncogenic RET Fusions or Mutations
Cancer Type
NCI ID
NCT04161391
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
52.
A Phase 1 / 2 Study of Visudyne (Liposomal Verteporfin) in Persons with Recurrent High Grade EGFR-Mutated Glioblastoma
Cancer Type
NCI ID
NCT04590664
Protocol IDs
WINSHIP5070-20
NCI-2020-05187
53.
A Phase 1 / 2, Dose Escalation Safety and Tolerability Study of AO-176 as Monotherapy and in Combination With Bortezomib and Dexamethasone in Adults With Relapsed or Refractory Multiple Myeloma
Cancer Type
NCI ID
NCT04445701
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
54.
A Phase 1 / 2, First-in-Human, Open-label, Dose Escalation Study of GB1275 Monotherapy and in Combination With an Anti-PD-1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma, Followed by Basket Expansion of GB1275 With Standard of Care or in Combination With an Anti-PD-1 Antibody in Patients With Specified Metastatic Solid Tumors
Cancer Type
NCI ID
NCT04060342
Protocol IDs
GB1275-1101 (KEYNOTE-A36)
NCI-2019-07310
GB1275-1101
55.
A Phase 1 / 2, Multicenter, Dose-Escalation and Expansion Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Subjects With Relapsed or Refractory Multiple Myeloma
Cancer Type
Lymphoma, Multiple Myeloma
NCI ID
NCT03314181
Protocol IDs
Treatment Sites (1)
Emory University Hospital - Atlanta
Atlanta
56.
A Phase 1 / 2, Multicenter, Open-label Study of FT-2102 as a Single Agent and in Combination With Azacitidine or Cytarabine in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome With an IDH1 Mutation
Cancer Type
Leukemia, Myelodysplastic Syndromes (MDS)
NCI ID
NCT02719574
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
57.
A Phase 1 / 2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C
Cancer Type
Unknown Primary
NCI ID
NCT03600883
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
58.
A Phase 1 / 2, Open-Label Study of ADXS-503 Alone and in Combination With Pembrolizumab in Subjects With Metastatic Squamous or Non-Squamous Non-Small Cell Lung Cancer
Cancer Type
Lung Cancer, Unknown Primary
NCI ID
NCT03847519
Protocol IDs
Treatment Sites (1)
Emory University Hospital - Atlanta
Atlanta
59.
A Phase 1 / 2, Open-Label, Multicenter Study to Investigate the Safety and Preliminary Efficacy of NKTR-214 in Combination With Pembrolizumab in Patients With Locally Advanced or Metastatic Solid Tumors
Cancer Type
NCI ID
NCT03138889
Protocol IDs
Treatment Sites (1)
Georgia Cancer Center at Augusta University
Augusta
60.
A Phase 1 / 2, Open-Label, Multicenter, Non-Randomized, Safety and Activity Study of HER2-Targeted Dual Switch CAR-T Cells (BPX-603) In Subjects With Previously Treated Advanced HER2-Positive Solid Tumors
Cancer Type
NCI ID
NCT04650451
Protocol IDs
BPX603-201A
NCI-2021-00052
61.
A Phase 1 / 2a Open-label Study to Investigate the Safety and Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of TAK-573 (Formerly TEV-48573) Administered Intravenously as a Single Agent in Patients With Refractory Multiple Myeloma
Cancer Type
Lymphoma, Multiple Myeloma
NCI ID
NCT03215030
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
62.
A Phase 1 / 2a Study to Evaluate the Safety and Preliminary Efficacy of Ibrutinib and Pembrolizumab in Patients with Mantle Cell Lymphoma (MCL)
Cancer Type
Lymphoma
NCI ID
NCT03153202
Protocol IDs
17-0554
NCI-2017-01538
63.
A Phase 1 Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Allogeneic CRISPR-Cas9-Engineered T Cells (CTX110) in Subjects With Relapsed or Refractory B-Cell Malignancies (CARBON)
Cancer Type
NCI ID
NCT04035434
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
64.
A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors
Cancer Type
Unknown Primary
NCI ID
NCT02817633
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
65.
A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an Anti-PD-1 Monoclonal Antibody, in Patients With Advanced Solid Tumors
Cancer Type
Unknown Primary
NCI ID
NCT02715284
Protocol IDs
4010-01-001
NCI-2016-01910
66.
A Phase 1 Dose-escalation Study of Radio- Labeled Antibody, FF-21101(90Y) for the Treatment of Advanced Cancer
Cancer Type
NCI ID
NCT02454010
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
67.
A Phase 1 Multicenter, Open-label Study to Assess the Safety, Pharmacokinetics and Preliminary Efficacy of CC-92480 in Combination With Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma
Cancer Type
Lymphoma, Multiple Myeloma
NCI ID
NCT03374085
Protocol IDs
Treatment Sites (1)
Emory Clinic
Atlanta
68.
A Phase 1 Multiple Ascending Dose Study of DS-3201b in Subjects With Lymphomas
Cancer Type
Leukemia, Lymphoma, Non-Hodgkin Lymphoma
NCI ID
NCT02732275
Protocol IDs
Treatment Sites (1)
Emory University School of Medicine
Atlanta
69.
A Phase 1 Multiple Dose Study to Evaluate the Safety and Tolerability of XmAb®14045 in Patients With CD123-Expressing Hematologic Malignancies
Cancer Type
Leukemia, Lymphoma, Myelodysplastic Syndromes (MDS), Skin Cancer (Non-Melanoma)
NCI ID
NCT02730312
Protocol IDs
Treatment Sites (4)
Blood and Marrow Transplant Group of Georgia
Atlanta
Emory University Hospital - Atlanta
Atlanta
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
70.
A Phase 1 Multiple Dose Study to Evaluate the Safety and Tolerability of XmAb®18087 in Subjects With Advanced Neuroendocrine and Gastrointestinal Stromal Tumors
Cancer Type
Colon/Rectal Cancer
NCI ID
NCT03411915
Protocol IDs
Treatment Sites (1)
Emory University Hospital - Atlanta
Atlanta
71.
A Phase 1 Multiple Dose Study to Evaluate the Safety and Tolerability of XmAb®20717 in Subjects With Selected Advanced Solid Tumors
Cancer Type
Endometrial Cancer
NCI ID
NCT03517488
Protocol IDs
Treatment Sites (1)
Emory University Hospital - Atlanta
Atlanta
72.
A Phase 1 Multiple-Dose Study to Evaluate the Safety and Tolerability of XmAb®22841 Monotherapy and in Combination With Pembrolizumab in Subjects With Selected Advanced Solid Tumors (DUET-4)
Cancer Type
Breast Cancer, Cervical Cancer, Colon/Rectal Cancer, Eye Cancer, Head and Neck Cancer, Kidney Cancer, Lung Cancer, Melanoma, Pancreatic Cancer, Prostate Cancer , Skin Cancer (Non-Melanoma), Stomach/ Gastric Cancer, Unknown Primary
NCI ID
NCT03849469
Protocol IDs
Treatment Sites (2)
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
73.
A Phase 1 Multiple-Dose Study to Evaluate the Safety and Tolerability of XmAb®23104 in Subjects With Selected Advanced Solid Tumors
Cancer Type
Lung Cancer
NCI ID
NCT03752398
Protocol IDs
Treatment Sites (1)
Emory University Hospital - Atlanta
Atlanta
74.
A Phase 1 Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 701 in Subjects With Multiple Myeloma
Cancer Type
Lymphoma, Multiple Myeloma
NCI ID
NCT03287908
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
75.
A Phase 1 Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies
Cancer Type
Lymphoma, Multiple Myeloma, Non-Hodgkin Lymphoma, Unknown Primary
NCI ID
NCT03424603
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
76.
A Phase 1 Study Evaluating the Safety, Tolerability and Pharmacokinetics of AMG 757 in Subjects With Small Cell Lung Cancer
Cancer Type
Lung Cancer, Skin Cancer (Non-Melanoma)
NCI ID
NCT03319940
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
77.
A Phase 1 Study of ABI-009 (NAB-RAPAMYCIN) in Pediatric Patients with Recurrent or Refractory Solid Tumors, including CNS Tumors as a Single Agent and in Combination with Temozolomide and Irinotecan
Cancer Type
Unknown Primary
NCI ID
NCT02975882
Protocol IDs
Treatment Sites (1)
Aflac Cancer and Blood Disorders Center of Children’s at Egleston
Atlanta
Howard M. Katzenstein, MD
404-785-0853
78.
A Phase 1 Study of ALKS 4230 Administered Subcutaneously as Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors (ARTISTRY-2)
Cancer Type
Unknown Primary
NCI ID
NCT03861793
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
79.
A Phase 1 Study of ASP1951 in Subjects With Advanced Solid Tumors
Cancer Type
Lung Cancer, Prostate Cancer , Unknown Primary
NCI ID
NCT03799003
Protocol IDs
Treatment Sites (1)
Emory University Hospital - Atlanta
Atlanta
80.
A Phase 1 Study of Aurora Kinase A Inhibitor LY3295668 Erbumine as a Single Agent and in Combination in Patients With Relapsed / Refractory Neuroblastoma
Cancer Type
NCI ID
NCT04106219
Protocol IDs
Treatment Sites (1)
Aflac Cancer and Blood Disorders Center of Children’s at Egleston
Atlanta
Howard M. Katzenstein, MD
404-785-0853
81.
A Phase 1 Study of CDX-1140 as Monotherapy or in Combination in Patients With Advanced Malignancies
Cancer Type
Head and Neck Cancer, Lung Cancer
NCI ID
NCT03329950
Protocol IDs
Treatment Sites (2)
Georgia Cancer Specialists - CenterPointe
Sandy Springs
Anila Lokhandwala
404-256-4777 ext 9242
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
82.
A Phase 1 Study of DS-3032b in Combination With Quizartinib in Subjects With FLT3-ITD Mutant Acute Myeloid Leukemia That Are Relapsed / Refractory, or Newly Diagnosed and Unfit for Intensive Chemotherapy
Cancer Type
NCI ID
NCT03552029
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
83.
A Phase 1 Study of Ipilimumab in Combination with Decitabine in Relapsed or Refractory Myelodysplastic Syndrome / Acute Myeloid Leukemia
Cancer Type
Myelodysplastic Syndromes (MDS)
NCI ID
NCT02890329
Protocol IDs
Treatment Sites (14)
Atlanta Cancer Care - Conyers
Conyers
404-303-3355
Atlanta Cancer Care - Stockbridge
Jonesboro
Andrena Jefferson
678 466-2069
Atlanta Cancer Care - Tower
Atlanta
404-303-3355
Atlanta Gynecologic Oncology
Atlanta
Jen Cuvo
404-303-3355
Georgia Cancer Specialists - Athens
Athens
Cynthia Pirkle
Georgia Cancer Specialists - Canton
Canton
Georgia Cancer Specialists - CenterPointe
Sandy Springs
Anila Lokhandwala
404-256-4777 ext 9242
Georgia Cancer Specialists - Kennestone
Marietta
Greta Dudley
Georgia Cancer Specialists - Macon-Coliseum
Macon
Sonia Hernandez
478-745-6130 x8152
Georgia Cancer Specialists - Stemmer
Decatur
Nina Patel
770-496-5555
Georgia Gynecologic Oncology
Atlanta
Jen Cuvo
404-303-3355
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
Northside Hospital Cancer Institute - Forsyth
Cumming
404-303-3355
University Gynecologic Oncology
Atlanta
Jen Cuvo
404-303-3355
84.
A Phase 1 Study of MK-3475 (Pembrolizumab) in Combination with Recombinant Interleukin-12 in Patients with Solid Tumors
Cancer Type
Unknown Primary
NCI ID
NCT03030378
Protocol IDs
Treatment Sites (3)
Emory Saint Joseph's Hospital
Atlanta
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
85.
A Phase 1 Study of NKX101, an Activating Chimeric Receptor Natural Killer Cell Therapy, in Subjects With Hematological Malignancies or Dysplasias
Cancer Type
NCI ID
NCT04623944
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
86.
A Phase 1 Study of Oral LOXO-292 in Patients With Advanced Solid Tumors, Including RET-Fusion Non-Small Cell Lung Cancer, Medullary Thyroid Cancer, and Other Tumors With Increased RET Activity
Cancer Type
Colon/Rectal Cancer, Lung Cancer, Skin Cancer (Non-Melanoma), Thyroid Cancer, Unknown Primary
NCI ID
NCT03157128
Protocol IDs
Treatment Sites (1)
Emory University School of Medicine
Atlanta
87.
A Phase 1 Study of Palbociclib in Combination with Cisplatin or Carboplatin in Advanced Solid Malignancies
Cancer Type
Unknown Primary
NCI ID
NCT02897375
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
88.
A Phase 1 Study of RGX-104, a Small Molecule LXR Agonist, in Patients With Advanced Solid Malignancies and Lymphoma With an Expansion in Select Malignancies
Cancer Type
Unknown Primary
NCI ID
NCT02922764
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
89.
A Phase 1 Study of Selinexor (KPT-330), a Selective XPO1 Inhibitor, in Recurrent and Refractory Pediatric Solid Tumors, Including CNS Tumors
Cancer Type
Brain Cancer , Eye Cancer, Non-Hodgkin Lymphoma, Unknown Primary
NCI ID
NCT02323880
Protocol IDs
Treatment Sites (1)
Aflac Cancer and Blood Disorders Center of Children’s at Egleston
Atlanta
Howard M. Katzenstein, MD
404-785-0853
90.
A Phase 1 Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies
Cancer Type
Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Leukemia, Lymphoma, Neuroblastoma
NCI ID
NCT03236857
Protocol IDs
Treatment Sites (1)
Aflac Cancer and Blood Disorders Center of Children’s at Egleston
Atlanta
Howard M. Katzenstein, MD
404-785-0853
91.
A PHASE 1 STUDY TO EVALUATE THE EFFECT OF HEPATIC IMPAIRMENT ON THE PHARMACOKINETICS AND SAFETY OF LORLATINIB IN ADVANCED CANCER PATIENTS
Cancer Type
Lymphoma, Unknown Primary
NCI ID
NCT03726333
Protocol IDs
Treatment Sites (3)
Emory Clinic
Atlanta
Emory University Hospital - Atlanta
Atlanta
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
92.
A Phase 1 Study Using Nab-Paclitaxel (Abraxane®) in Combination with Gemcitabine for Pediatric Relapsed and Refractory Solid Tumors
Cancer Type
NCI ID
NCT03507491
Protocol IDs
Treatment Sites (1)
Aflac Cancer and Blood Disorders Center of Children’s at Egleston
Atlanta
Howard M. Katzenstein, MD
404-785-0853
93.
A Phase 1 Trial of the CD123 X CD3 Dual Affinity Re-Targeting Antibody Flotetuzumab (NSC#808294) in Children, Adolescents, and Young Adults with Relapsed or Refractory Acute Myeloid Leukemia
Cancer Type
NCI ID
NCT04158739
Protocol IDs
PEPN1812
PEPN1812
NCI-2019-06780
94.
A Phase 1 Trial to Evaluate the Potential Impact of Renal Impairment on the Pharmacokinetics and Safety of CPX-351 (Daunorubicin and Cytarabine) Liposome for Injection Treatment in Adult Patients With Hematologic Malignancies
Cancer Type
Lymphoma, Myelodysplastic Syndromes (MDS)
NCI ID
NCT03555955
Protocol IDs
Treatment Sites (2)
Atlanta Cancer Care - Conyers
Conyers
404-303-3355
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
95.
A Phase 1 Trial using Everolimus in Combination with Nelarabine, Cyclophosphamide and Etoposide in Relapsed T cell Lymphoblastic Leukemia / Lymphoma
Cancer Type
Lymphoma
NCI ID
NCT03328104
Protocol IDs
Treatment Sites (1)
Aflac Cancer and Blood Disorders Center of Children’s at Egleston
Atlanta
Howard M. Katzenstein, MD
404-785-0853
96.
A Phase 1, Dose Escalation and Expansion Study of Engineered Donor Grafts Derived From Mobilized Peripheral Blood (OrcaGraft), With Single Agent Graft Versus-host Disease Prophylaxis, in Recipients Undergoing Myeloablative Allogeneic Hematopoietic Cell Transplantation for Hematologic Malignancies
Cancer Type
Myelodysplastic Syndromes (MDS)
NCI ID
NCT03802695
Protocol IDs
Treatment Sites (1)
Emory University Hospital - Atlanta
Atlanta
97.
A Phase 1, First in Human, Dose Escalation Study of MGD006, a CD123 x CD3 Dual Affinity Re-Targeting (DART) Bi-Specific Antibody Based Molecule, in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Cancer Type
Leukemia
NCI ID
NCT02152956
Protocol IDs
Treatment Sites (1)
Emory University Hospital - Atlanta
Atlanta
98.
A Phase 1, First-in-Human, Open-Label, Dose Escalation and Expansion Study of CUE-101 Monotherapy in Patients With HPV+ Recurrent / Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
Cancer Type
Skin Cancer (Non-Melanoma), Unknown Primary
NCI ID
NCT03978689
Protocol IDs
Treatment Sites (1)
Emory University Hospital - Atlanta
Atlanta
99.
A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of Teclistamab, a Humanized BCMA x CD3 DuoBody® Antibody in Subjects With Relapsed or Refractory Multiple Myeloma
Cancer Type
NCI ID
NCT03145181
Protocol IDs
CR108206
NCI-2017-01157
64007957MMY1001
2016-002122-36
100.
A Phase 1, Multicenter, Open-Label Study of JCAR017, CD19-targeted Chimeric Antigen Receptor (CAR) T Cells, for Relapsed and Refractory (R / R) B-cell Non-Hodgkin Lymphoma (NHL)
Cancer Type
Lymphoma, Non-Hodgkin Lymphoma
NCI ID
NCT02631044
Protocol IDs
Treatment Sites (1)
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
101.
A Phase 1, Multicenter, Open-Label, Dose-Escalation and Expansion Study of Intravenously Administered IO-202 in Patients With Relapsed / Refractory Acute Myeloid Leukemia (AML) and Chronic Myelomonocytic Leukemia (CMML)
Cancer Type
NCI ID
NCT04372433
Protocol IDs
IO-202-CL-001
NCI-2020-07121
102.
A Phase 1, Open-Label Study of ABSK021 to Assess Safety, Tolerability, and Pharmacokinetics in Patients With Advanced Solid Tumor
Cancer Type
NCI ID
NCT04192344
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
103.
A Phase 1, Open-label Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of Oral EPI-7386 in Patients With Metastatic Castration-Resistant Prostate Cancer
Cancer Type
NCI ID
NCT04421222
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
104.
A Phase 1, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMPL-689 in Patients With Relapsed or Refractory Lymphoma
Cancer Type
NCI ID
NCT03786926
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
105.
A Phase 1, Open-label, Dose Finding Study of CC-93269, a BCMA X CD3 T Cell Engaging Antibody, in Subjects With Relapsed and Refractory Multiple Myeloma.
Cancer Type
Lymphoma, Multiple Myeloma
NCI ID
NCT03486067
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
106.
A Phase 1, Open-Label, Dose-Escalation and Cohort Expansion First-in-Human Study of the Safety, Tolerability, Activity and Pharmacokinetics of REGN3767 (Anti-LAG-3 mAb) Administered Alone or in Combination With REGN2810 (Anti-PD-1 mAb) in Patients With Advanced Malignancies
Cancer Type
Lymphoma, Unknown Primary
NCI ID
NCT03005782
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
107.
A Phase 1, Open-label, Multicenter Study to Evaluate the Safety of bb2121 in Subjects With High Risk, Newly Diagnosed Multiple Myeloma (KarMMa-4)
Cancer Type
NCI ID
NCT04196491
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
108.
A Phase 1, Open-label, Multi-center, Dose Escalation and Dose Expansion Study of NKTR-255 as a Single Agent in Relapsed or Refractory Hematological Malignancies and in Combination With Daratumumab as a Salvage Regimen for Multiple Myeloma
Cancer Type
NCI ID
NCT04136756
Protocol IDs
18-255-02
NCI-2019-07642
109.
A Phase 1, Open-Label, Multicenter, Dose Escalation and Expansion Study of ONCR-177, an Oncolytic Herpes Simplex Virus for Intratumoral Injection, Alone and in Combination With PD-1 Blockade in Adult Subjects With Advanced and / or Refractory Cutaneous, Subcutaneous or Metastatic Nodal Solid Tumors
Cancer Type
NCI ID
NCT04348916
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
110.
A Phase 1, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Ascending Doses of AZD5991 in Subjects With Relapsed or Refractory Haematologic Malignancies
Cancer Type
Hodgkin Lymphoma, Leukemia, Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes (MDS), Non-Hodgkin Lymphoma, Skin Cancer (Non-Melanoma), Unknown Primary
NCI ID
NCT03218683
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
111.
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis
Cancer Type
NCI ID
NCT04279847
Protocol IDs
INCB 57643-103
NCI-2020-07097
112.
A Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of CPI-444 as Single Agent and in Combination With Atezolizumab in Patients With Selected Incurable Cancers
Cancer Type
Oral Cancer
NCI ID
NCT02655822
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
113.
A Phase 1/2a Study of BMS-986205 Administered in Combination With Nivolumab (BMS-936558, Anti-PD-1 Monoclonal Antibody) in Advanced Malignant Tumors
Cancer Type
Unknown Primary
NCI ID
NCT02658890
Protocol IDs
Treatment Sites (2)
Georgia Cancer Specialists - CenterPointe
Sandy Springs
Anila Lokhandwala
404-256-4777 ext 9242
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
114.
A Phase 1b / 2 Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics,Pharmacodynamics, and Efficacy of AMG 592 inAdult Subjects With Steroid Refractory Chronic Graft Versus Host Disease
Cancer Type
NCI ID
NCT03422627
Protocol IDs
20160283
NCI-2018-00330
2017-000763-33
115.
A Phase 1b / 2 Open-label Study To Evaluate Safety, Clinical Activity, Pharmacokinetics And Pharmacodynamics Of Avelumab (msb0010718c) In Combination With Other Cancer Immunotherapies In Patients With Advanced Malignancies
Cancer Type
Breast Cancer, Lung Cancer, Melanoma, Ovarian Cancer, Skin Cancer (Non-Melanoma), Stomach/ Gastric Cancer, Unknown Primary
NCI ID
NCT02554812
Protocol IDs
B9991004
NCI-2015-02263
2015-002552-27
JAVELIN MEDLEY
s16-02110
116.
A Phase 1b / 2 Open-Label, Dose Escalation & Expansion Study of Orally Administered VRx-3996 & Valganciclovir in Subjects With Epstein-Barr Virus-Associated Lymphoid Malignancies
Cancer Type
NCI ID
NCT03397706
Protocol IDs
VT3996-201
NCI-2018-00416
117.
A Phase 1b / 2 Study of Derazantinib as Monotherapy and Combination Therapy With Paclitaxel, Ramucirumab or Atezolizumab in Patients With HER2-negative Gastric Adenocarcinoma Expressing FGFR2 Genetic Aberrations
Cancer Type
NCI ID
NCT04604132
Protocol IDs
DZB-CS-202
NCI-2021-01098
118.
A Phase 1b / 2 Study to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of Oleclumab (MEDI9447) With or Without Durvalumab in Combination With Chemotherapy in Subjects With Metastatic Pancreatic Ductal Adenocarcinoma
Cancer Type
Pancreatic Cancer, Unknown Primary
NCI ID
NCT03611556
Protocol IDs
D6070C00005
NCI-2018-01724
D6070C00005
119.
A Phase 1b / 2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of EQ001 in Subjects With Newly Diagnosed Acute Graft Versus Host Disease
Cancer Type
Bone and Soft Tissue (including Sarcoma)
NCI ID
NCT03763318
Protocol IDs
Treatment Sites (1)
Emory University Hospital - Atlanta
Atlanta
120.
A Phase 1b / 2, Open Label, Dose Escalation and Expansion Study of the Glutaminase Inhibitor Telaglenastat (CB-839) in Combination With CDK4 / 6 Inhibitor Palbociclib in Patients With Advanced or Metastatic Solid Tumors
Cancer Type
NCI ID
NCT03965845
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
121.
A Phase 1b / 2, Open-Label, Multicenter Dose-Escalation and Dose-Expansion Study of the Combination of RMC-4630 and Cobimetinib in Adult Participants With Relapsed / Refractory Solid Tumors With Specific Genomic Aberrations
Cancer Type
Unknown Primary
NCI ID
NCT03989115
Protocol IDs
Treatment Sites (2)
Emory University Hospital - Atlanta
Atlanta
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
122.
A Phase 1b / 2a Pilot Randomized Study to Evaluate the Safety and Tolerability of Autologous T-Cells Expressing Enhanced TCRs (T Cell Receptors) Specific for NY-ESO-1 / LAGE-1a (GSK3377794) Alone, or in Combination With Pembrolizumab in HLA-A2+ Participants With NY-ESO-1- or LAGE-1a-Positive Advanced or Recurrent Non-Small Cell Lung Cancer
Cancer Type
Lung Cancer, Unknown Primary
NCI ID
NCT03709706
Protocol IDs
Treatment Sites (2)
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
123.
A Phase 1b Dose-escalation and Dose-expansion Study of Enfortumab Vedotin (ASG-22CE) in Combination With Immune Checkpoint Inhibitor (CPI) Therapy for Treatment of Patients With Locally Advanced or Metastatic Urothelial Cancer
Cancer Type
Bladder Cancer, Kidney Cancer, Unknown Primary
NCI ID
NCT03288545
Protocol IDs
Treatment Sites (2)
Piedmont Cancer Institute
Atlanta
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
124.
A Phase 1b Neoadjuvant Trial of Sirolimus Followed by Durvalumab (MEDI4736) in Resectable Non-Small Cell Lung Cancer
Cancer Type
NCI ID
NCT04348292
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
125.
A Phase 1b, First-in-Human, Dose Escalation and Expansion Study of XMT-1536 In Patients With Solid Tumors Likely to Express NaPi2b
Cancer Type
NCI ID
NCT03319628
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
126.
A Phase 1b-2 Study of the ROR1-Targeting Monoclonal Antibody, Cirmtuzumab, and the Bruton Tyrosine Kinase Inhibitor, Ibrutinib, in Patients With B-Cell Lymphoid Malignancies
Cancer Type
Leukemia, Lymphoma
NCI ID
NCT03420183
Protocol IDs
Treatment Sites (3)
Emory Saint Joseph's Hospital
Atlanta
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
127.
A Phase 1b-2 Study of the ROR1-Targeting Monoclonal Antibody, Cirmtuzumab, and the Bruton Tyrosine Kinase Inhibitor, Ibrutinib, in Patients with B-Cell Lymphoid Malignancies
Cancer Type
NCI ID
NCT03088878
Protocol IDs
170127
NCI-2018-01703
NCT03420183
128.
A Phase 2 / 3, Multicenter, randOmized, Double-blind, Placebo-controlled, stUdy to evaLuate the Safety and Efficacy of Alpha-1 AntiTrypsin for the prEvention of Graft Versus-host Disease in Patients Receiving Hematopoietic Cell Transplant (MODULAATE Study)
Cancer Type
Myelodysplastic Syndromes (MDS)
NCI ID
NCT03805789
Protocol IDs
Treatment Sites (1)
Emory University Hospital - Atlanta
Atlanta
129.
A Phase 2 Evaluation of Daratumumab-Based Treatment in Newly Diagnosed Multiple Myeloma Patients with Renal Insufficiency
Cancer Type
NCI ID
NCT04352205
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
130.
A Phase 2 Front-Line PET / CT-2 Response-Adapted Brentuximab Vedotin and Nivolumab Incorporated and Radiation-Free Management of Early Stage Classical Hodgkin Lymphoma (cHL)
Cancer Type
Lymphoma
NCI ID
NCT03712202
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
131.
A Phase 2 Randomized Study of Irinotecan / Temozolomide / Dinutuximab with or without Eflornithine (DFMO) in Children with Relapsed, Refractory or Progressive Neuroblastoma
Cancer Type
Neuroblastoma
NCI ID
NCT03794349
Protocol IDs
Treatment Sites (2)
Aflac Cancer and Blood Disorders Center of Children’s at Egleston
Atlanta
Howard M. Katzenstein, MD
404-785-0853
Curtis and Elizabeth Anderson Cancer Institute at Memorial University Medical Center
Savannah
Joni N. Shortt, RN, BSN, CCRC
912-350-8913
132.
A Phase 2 Randomized, Multicenter, Double-Blind Study of the Glutaminase Inhibitor Telaglenastat With Pembrolizumab and Chemotherapy Versus Placebo With Pembrolizumab and Chemotherapy in First-Line, Metastatic KEAP1 / NRF2-Mutated, Nonsquamous, Non-Small Cell Lung Cancer (NSCLC)
Cancer Type
NCI ID
NCT04265534
Protocol IDs
CX-839-014
NCI-2020-04529
133.
A Phase 2 Study of Anti-PD-L1 Antibody (Atezolizumab) in Alveolar Soft Part Sarcoma
Cancer Type
Bone and Soft Tissue (including Sarcoma)
NCI ID
NCT03141684
Protocol IDs
Treatment Sites (1)
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
134.
A Phase 2 Study of Anti-PD-L1 Antibody (Atezolizumab) in Chondrosarcoma and Clear Cell Sarcoma
Cancer Type
NCI ID
NCT04458922
Protocol IDs
10398
10398
NCI-2020-04634
000081
20-C-XXXX
135.
A Phase 2 Study of Atezolizumab and Cobimetinib in PD-1 / PD-L1 Inhibitor Resistant or Refractory Non-Small Cell Lung Cancer
Cancer Type
NCI ID
NCT03600701
Protocol IDs
Treatment Sites (3)
Emory Saint Joseph's Hospital
Atlanta
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
136.
A Phase 2 Study of Blinatumomab (NSC# 765986) in Combination with Nivolumab (NSC # 748726), a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged = 1 to < 31 Years Old with First Relapse
Cancer Type
NCI ID
NCT04546399
Protocol IDs
Treatment Sites (1)
Curtis and Elizabeth Anderson Cancer Institute at Memorial University Medical Center
Savannah
Joni N. Shortt, RN, BSN, CCRC
912-350-8913
137.
A Phase 2 Study of Dabrafenib (NSC# 763760) with Trametinib (NSC# 763093) after Local Irradiation in Newly-Diagnosed BRAF V600-Mutant High-Grade Glioma (HGG)
Cancer Type
NCI ID
NCT03919071
Protocol IDs
Treatment Sites (1)
Curtis and Elizabeth Anderson Cancer Institute at Memorial University Medical Center
Savannah
Joni N. Shortt, RN, BSN, CCRC
912-350-8913
138.
A Phase 2 Study of Docetaxel, Ramucirumab, and Pembrolizumab for Patients with Metastatic or Recurrent Non-Small Cell Lung Cancer Who Progressed on Platinum-Doublet and PD-1 / PD-L1 Blockade
Cancer Type
NCI ID
NCT04340882
Protocol IDs
Treatment Sites (2)
Atlanta VA Medical Center
Decatur
Scott Edelman
404-728-7680
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
139.
A Phase 2 Study of Erdafitinib in Subjects With Advanced Solid Tumors and FGFR Gene Alterations
Cancer Type
NCI ID
NCT04083976
Protocol IDs
Treatment Sites (2)
Emory University Hospital - Atlanta
Atlanta
University Cancer and Blood Center, LLC - Athens Medical Oncology
Athens
Jamie Hodgson
706-353-2990 x279
140.
A Phase 2 Study of Inotuzumab Ozogamicin (NSC# 772518) in Children and Young Adults with Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL)
Cancer Type
Lymphoma
NCI ID
NCT02981628
Protocol IDs
Treatment Sites (1)
Curtis and Elizabeth Anderson Cancer Institute at Memorial University Medical Center
Savannah
Joni N. Shortt, RN, BSN, CCRC
912-350-8913
141.
A Phase 2 Study of Lenvatinib in Combination with Radioactive Iodine Therapy in Patients with Progressive RAI-Sensitive Differentiated Thyroid Cancer
Cancer Type
Thyroid Cancer
NCI ID
NCT03506048
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
142.
A Phase 2 Study of Neoadjuvant Cabozantinib in Patients with Locally Advanced Non-Metastatic Clear Cell Renal Cell Carcinoma
Cancer Type
Kidney Cancer, Unknown Primary
NCI ID
NCT04022343
Protocol IDs
Treatment Sites (2)
Emory University Hospital - Atlanta
Atlanta
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
143.
A Phase 2 Study of Olaparib in Combination With Pembrolizumab in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) and / or Homologous Recombination Deficiency (HRD)-Positive Advanced Cancer
Cancer Type
NCI ID
NCT04123366
Protocol IDs
7339-007
NCI-2019-08758
2019-001745-40
MK-7339-007
KEYLYNK-007
144.
A Phase 2 Study of Olaparib Monotherapy in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer
Cancer Type
Unknown Primary
NCI ID
NCT03742895
Protocol IDs
Treatment Sites (2)
Augusta University Medical Center
Augusta
Carol Terry
706-721-4430
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
145.
A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients
Cancer Type
NCI ID
NCT02724579
Protocol IDs
Treatment Sites (1)
Curtis and Elizabeth Anderson Cancer Institute at Memorial University Medical Center
Savannah
Joni N. Shortt, RN, BSN, CCRC
912-350-8913
146.
A Phase 2 Study of the JAK1/JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High-Risk CRLF2-Rearranged and/or JAK Pathway-Mutant Acute Lymphoblastic Leukemia
Cancer Type
Acute Lymphoblastic Leukemia
NCI ID
NCT02723994
Protocol IDs
Treatment Sites (1)
Aflac Cancer and Blood Disorders Center of Children’s at Egleston
Atlanta
Howard M. Katzenstein, MD
404-785-0853
147.
A Phase 2 Study of the MEK Inhibitor Trametinib (NSC# 763093) in Children with Relapsed or Refractory Juvenile Myelomonocytic Leukemia
Cancer Type
Myelodysplastic Syndromes (MDS)
NCI ID
NCT03190915
Protocol IDs
Treatment Sites (1)
Aflac Cancer and Blood Disorders Center of Children’s at Egleston
Atlanta
Howard M. Katzenstein, MD
404-785-0853
148.
A Phase 2 Study of the PARP Inhibitor Olaparib (AZD2281) in IDH1 and IDH2 Mutant Advanced Solid Tumors
Cancer Type
NCI ID
NCT03212274
Protocol IDs
Treatment Sites (3)
Emory Saint Joseph's Hospital
Atlanta
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
149.
A Phase 2 Study of Veliparib (ABT-888) and Local Irradiation, Followed by Maintenance Veliparib and Temozolomide, in Patients with Newly Diagnosed High-Grade Glioma (HGG) without H3 K27M or BRAFV600E Mutations
Cancer Type
NCI ID